These findings support the notion that vitamin D’s clinical benefit in AD likely extends beyond classical calcium homeostasis, involving regulation of innate antimicrobial peptides (e.g., cathelicidin LL-37), restoration of filaggrin expression, as well as modulation of IL-4/IL-13-driven inflammation. The gene discussed is IL4; the disease is Alzheimer disease.